|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Abu-Khalaf MM et al. Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology 2005;69(5):372-83. Abstract
Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract
Berry DA et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB & US Breast Intergroup. Breast Cancer Res Treat 2004;88(Suppl 1);Abstract 29.
Blagosklonny MV et al. How Avastin potentiates chemotherapeutic drugs: Action and reaction in antiangiogenic therapy. Cancer Biol Ther 2005;4(12):1307-10. Abstract
Campone M et al. Taxanes in adjuvant breast cancer setting: Which standard in Europe? Crit Rev Oncol Hematol 2005;55(3):167-75. Abstract
Citron ML et al. Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG. J Clin Oncol 2005;23(Suppl 16);Abstract 620.
Dougherty MK et al. Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 2004;3(5):460-7. Abstract
Fornier M, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res 2005;7(2):64-9. Abstract
Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract
Green MR et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17(8):1263-8. Abstract
Hayes DF et al. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. Proc Am Soc Clin Oncol 2006;24(Suppl):5;Abstract 510.
Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res Treat 2005;94(Suppl 1);Abstract 41.
Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62. Abstract
Lane TF et al. SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 1994;125(4):929-43. Abstract
Muss HB et al; Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005;293(9):1073-81. Abstract
Robert NJ et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol 2004;31(6 Suppl 13):106-46. Abstract
Sartor CI et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and leukemia group B 9344. J Clin Oncol 2005;23(1):30-40. Abstract
Schwartz J et al. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 2005;16(2):247-52. Abstract
Slamon DJ et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82. Abstract
Winer EP et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. J Clin Oncol 2004;22(11):2061-8. Abstract
 |
 |
Editor’s Note:
Reality check
Interviews
Marc E Lippman, MD
- Select publications
C Kent Osborne, MD
- Select publications
I Craig Henderson, MD
- Select publications
Charles E Geyer Jr, MD
- Select publications
Frank A Vicini, MD
- Select publications
Miami Beach Cancer Conference Tumor Panel Discussion on Systemic Therapy of Metastatic Disease
- Select publications
 |
 |
 |
 |
 |
